Health tech companies use software, data, devices, and digital platforms to improve how healthcare is delivered, accessed, or managed. They sit at the intersection of medicine and technology and the space has grown significantly over the past decade.
What Counts as a Health Tech Company?
The term gets used loosely, which causes real confusion. A health tech company is generally one whose core product is a technology software, a platform, a connected device, or a data system applied to a healthcare problem. That's what separates it from a hospital, a pharmaceutical manufacturer, or a traditional medical device company.
What's often overlooked is how broad this actually is. A company building appointment-booking software is health tech. So is one using AI to read diagnostic scans. So is a wearable that tracks heart rate. The common thread is technology doing the heavy lifting not just supporting a clinical process, but being central to it.
A few useful distinctions worth keeping clear:
|
Term |
What It Typically Covers |
Key Difference from Health Tech |
|
Health Tech |
Software, platforms, data tools, digital devices |
Technology is the core product |
|
Medtech |
Physical medical devices (scanners, implants, instruments) |
Hardware-focused, often more regulated |
|
Biotech |
Biological research, drug development, gene therapy |
Science-focused, not primarily software |
|
Digital Health |
Overlaps heavily with health tech; sometimes used interchangeably |
Broader term, less precise |
In practice, these categories blur constantly. A company like Tempus AI works with genomic data and clinical records.
Is that health tech, biotech, or AI? Most people in the industry would say all three. The label matters less than understanding what the company actually does.
Major Sub-Sectors Within Health Tech Companies
Health tech isn't one industry it's a cluster of quite different businesses that happen to share a common ingredient: technology applied to health. Breaking it down by sub-sector makes the landscape much easier to understand.
Telehealth and Virtual Care
These companies connect patients with clinicians remotely via video, messaging, or asynchronous tools. The model existed before 2020, but expanded sharply during the pandemic and never fully contracted.
Companies in this space include platforms for general consultations, specialist referrals, and condition-specific care. Zocdoc, K Health, and KRY (Sweden) are examples across different parts of the market.
In practice, telehealth companies tend to generate revenue either through per-visit fees, employer benefit arrangements, or insurance reimbursement and the reimbursement piece remains a moving target depending on geography.
AI and Data Analytics in Healthcare
This is currently the most active and well-funded sub-sector. Companies here build tools that help clinicians make better decisions faster reading scans, flagging anomalies, predicting patient deterioration, or matching patients to clinical trials. Qure AI, Tempus AI, and Flatiron Health operate in this space.
The reason this segment attracts so much investment is straightforward: healthcare generates enormous amounts of data, and most of it has historically been underused. AI creates a plausible path to extracting clinical value from that data at scale.
This mirrors broader trends seen in AI companion and decision-support platforms, where personalised, data-driven interaction is increasingly central to the product.
Medical Devices and Wearables
Connected health devices, smartwatches, continuous glucose monitors, sleep trackers, digital stethoscopes fall here. Oura's ring, Whoop's fitness band, and Neuralink's neural interface work are all distinct points on this spectrum. What these companies share is hardware paired with software and data analysis.
Mental Health Technology
Mental health tech has grown substantially, partly in response to well-documented gaps in access to traditional mental health services. Companies like Lyra Health, Spring Health, and Headway work on different parts of the problem, employer-facing mental health benefits, therapist networks, and insurance-accessible therapy platforms respectively.
Precision Medicine and Genomics
These companies use genetic, molecular, and clinical data to tailor treatments to individual patients rather than applying population-level protocols. This sub-sector sits closest to biotech but remains meaningfully health tech when the primary innovation is in data interpretation and clinical application. Tempus, Caris Life Sciences, and Generate Biomedicines operate here.
Health Records and Data Infrastructure
Less visible to patients, but foundational to the rest of the sector. Companies building electronic health record systems, data exchange platforms, and interoperability tools keep clinical information moving between providers, insurers, and patients. PointClickCare and Datavant are examples.
Clinical Trials Technology
Running clinical trials is expensive and slow. Companies like Reify Health and Medable build software that speeds up trial recruitment, data capture, and participant management. Formation Bio takes a related approach using technology to develop drugs more efficiently after acquiring clinical-stage compounds.
Pharmacy and Medication Management
Digital pharmacy platforms, prescription discount tools, and medication delivery services sit here. GoodRx, PharmEasy (India), and Truepill each approach medication access differently but share the goal of reducing friction between patients and the drugs they need.
Prevention and Chronic Care Management
Interestingly, this is the weakest sub-sector in terms of high-performing companies, despite being widely recognised as the area with the greatest potential for long-term cost reduction.
Companies like Virta Health (type 2 diabetes reversal) and Noom (weight management) work here. The challenge is that prevention is hard to monetise quickly, and the healthcare system as a whole has historically paid for treatment rather than avoidance of disease.
Notable Health Tech Companies and What They Do
Rather than list every company, it's more useful to understand the different types playing different roles.Tempus AI sits at the high end of data complexity it manages one of the largest libraries of multimodal clinical and molecular data and uses it to help oncologists personalise treatment decisions. It also connects patients to clinical trials.
Zocdoc solves a simpler but still genuine problem: helping patients find in-network doctors and book appointments without phone calls. The simplicity of the problem doesn't diminish its value; booking friction has historically caused patients to delay or avoid care altogether.
GoodRx built a marketplace for prescription discounts, accepted at over 70,000 US pharmacies. The business model is essentially a negotiated discount network GoodRx negotiates lower prices from pharmacy benefit managers and passes savings to consumers.
Oura produces a wearable ring that tracks sleep, heart rate, and activity. It's notable because the device itself is simple; the value proposition is the quality of the data interpretation behind it.
Flatiron Health focuses specifically on oncology, building technology infrastructure for cancer centres and converting real-world patient data into evidence that can improve treatment decisions and inform policy.
These companies are very different from one another. What's often overlooked in broad "health tech" coverage is that grouping them together can obscure more than it reveals.
A Note on Unicorn Valuations
Several health tech companies are classed as unicorns privately held companies valued at over $1 billion. As of early 2023, over 140 health tech unicorns existed globally, collectively valued at over $320 billion, according to Wikipedia's list of unicorn startup companies. The US accounts for the large majority of these.
Unicorn status is a fundraising signal, not a measure of clinical impact or profitability. Some companies reach high valuations before establishing sustainable revenue. Teams in this space commonly note that a high valuation in a funding round reflects investor expectations, not confirmed financial performance.
How Health Tech Companies Make Money
This is where most general coverage falls short. The business model varies significantly by sub-sector.
|
Business Model |
Common in |
How It Works |
|
SaaS / Subscription |
Analytics, EHR, clinical trials software |
Recurring fees paid by hospitals, clinics, or employers |
|
Per-visit / Per-transaction |
Telehealth, digital pharmacy |
Fee charged per consultation or prescription fulfilled |
|
Data licensing |
Genomics, analytics platforms |
Anonymised data sold or licensed to pharma and research organisations |
|
Employer / insurer contracts |
Mental health tech, chronic care |
Annual contracts with self-insured employers or health plans |
|
Device + recurring services |
Wearables, connected devices |
Hardware sale followed by subscription for app access or data insights |
|
Marketplace / discount network |
Prescription platforms |
Commission or spread on negotiated pricing between parties |
In practice, most health tech companies blend two or more of these. A telehealth platform might charge per visit to individuals while also holding an employer contract for bulk employee access.
What makes the economics complicated is that healthcare payment in most countries involves at least three parties: the patient, the provider, and the payer (insurer or government). Health tech companies have to navigate all three, and building around insurance reimbursement in particular requires significant regulatory and operational investment.
Also Read: Coyyn.com Business
What Is Driving Growth in Health Tech
Several structural factors have been pushing this sector for a decade and show no sign of reversing.
Aging populations. Older populations require more care, more chronic disease management, and more interaction with health systems. Technology that scales clinical capacity whether through remote monitoring or AI-assisted diagnosis becomes more valuable as this demand grows.
AI capability growth. The practical ability to train models on large datasets has improved significantly. In healthcare, this opens genuine applications in diagnostics, drug discovery, and clinical decision support that weren't feasible at scale five years ago.
Changing patient expectations. Patients increasingly expect the kind of transparency, convenience, and self-service access in healthcare that they experience in retail or financial services. Digital health companies are, in part, filling a gap left by systems that were designed around provider convenience rather than patient experience.
Employer cost pressure. Large employers in the US, who often self-insure their employees, have become significant buyers of health tech products particularly in mental health, chronic care, and benefits navigation.
This has opened a substantial B2B market that didn't exist in the same form 15 years ago. For health tech founders navigating this landscape, having access to the right startup tools can make a meaningful difference in how efficiently a business scales.
Post-pandemic infrastructure. Regulatory and cultural barriers to virtual care dropped sharply after 2020. Many of those changes have become permanent, giving telehealth and remote monitoring companies a more stable foundation.
Challenges Health Tech Companies Face
Growth in this space is real but so are the obstacles. Several of these challenges are structural, not temporary.
Regulatory Compliance
Health tech companies that touch clinical decisions face significant regulatory scrutiny. In the US, the FDA has expanded its oversight of software as a medical device (SaMD). Getting regulatory clearance takes time and resources, and the standards are evolving. Companies that operate across multiple countries face layered requirements.
Data Privacy
Health data is among the most sensitive personal information that exists. In the US, HIPAA sets baseline requirements for how patient data is handled. In Europe, GDPR adds further constraints.
Building secure, compliant data infrastructure is not optional; it's table stakes. Organisations in this space typically find that data governance costs are consistently underestimated at the early stage.
Reimbursement Barriers
Having a clinically effective product is necessary but not sufficient. If insurers won't reimburse it, most patients won't pay out of pocket. The reimbursement process is slow, varies by payer, and often requires clinical evidence at a level that takes years to accumulate. This is a primary reason why prevention-focused companies struggle to scale despite operating in a high-value space.
Clinical Adoption
Getting clinicians to change established workflows is harder than building the technology itself. Physicians are time-pressured and appropriately cautious about tools that affect patient care. Teams commonly report that sales cycles in health tech are longer than in other enterprise software markets for exactly this reason.
Interoperability
Health data sits in fragmented systems that don't communicate well. Electronic health records from different vendors often can't exchange data cleanly. Until this is solved at a systems level, health tech companies building on top of that infrastructure face ongoing friction.
Health Tech by Geography
The US dominates this sector by a significant margin both in number of companies and total investment. This reflects several factors: the size of the US healthcare market, the volume of venture capital available, and the relative willingness of large US employers and insurers to adopt new solutions.
Outside the US, distinct ecosystems have developed:
- Europe: France's Doctolib built a large appointment-booking and teleconsultation platform. Sweden's KRY operates virtual GP services. France's Alan is a technology-first health insurer. Germany's Otto Bock focuses on prosthetics and orthotic devices.
- China: WeDoctor (GuaHao) and Medlinker have built large telehealth platforms serving a population with significant demand for remote healthcare access. Both reached high valuations quickly given the scale of the addressable market.
- India: PharmEasy and Pristyn Care have scaled in the pharmacy and surgical care space respectively, operating in a market where healthcare access gaps are significant and digital infrastructure has expanded rapidly.
What's often overlooked in global comparisons is that regulatory environments shape the market as much as technology does. What's commercially viable in one country may be legally constrained in another.
How to Evaluate a Health Tech Company
Whether you're a patient, a clinician, an employer, or an investor, a few questions cut through most of the marketing noise.
Is there clinical evidence? A company's claims about improving outcomes should be backed by published studies or at minimum rigorous internal data. Marketing language about "transforming healthcare" without evidence of effect is common and worth treating with skepticism.
What is the regulatory status? Has the product received FDA clearance, CE marking, or equivalent? For anything touching clinical decisions, this matters.
Who pays for it? Understanding whether a product is reimbursed by insurance or sold direct-to-consumer tells you a lot about its commercial viability and the likely durability of its revenue.
How is patient data handled? Privacy policy, data sharing practices, and whether data is sold or licensed to third parties are all relevant and not always disclosed prominently.
Is the business model sustainable? High valuations and large funding rounds are not the same as viable economics. In practice, some health tech companies have raised significant capital while running persistent losses in markets where reimbursement remains uncertain.
Conclusion
Health tech companies cover a wide range of businesses from telehealth platforms and wearable devices to AI diagnostics and genomics tools. The sector is growing, but it's not uniform.
Business models, regulatory requirements, and market maturity vary substantially by sub-sector and geography. Understanding these differences matters more than tracking any single company or funding headline.
Frequently Asked Questions
What is the difference between health tech and medtech?
Health tech typically refers to software, platforms, and data-driven tools. Medtech usually refers to physical medical devices, scanners, implants, surgical instruments. The lines blur when devices include software components, which is increasingly common.
Are health tech companies profitable?
Many are not, particularly at early and growth stages. The sector attracts large amounts of venture capital, and companies often prioritise scaling over profitability. Publicly listed health tech companies show mixed financial results.
What are the biggest health tech companies by valuation?
Among private companies, Devoted Health, Biosplice Therapeutics, and Tempus have reached the highest valuations. Among publicly traded companies, the picture changes large incumbents like Epic Systems (private) and established players in diagnostics and health IT are significantly larger.
Is health tech the same as digital health?
The terms are used interchangeably in most contexts. Digital health is the broader term and sometimes includes things like health-focused mobile apps that may not qualify as health tech under stricter definitions. Neither term has a single agreed regulatory or industry definition.
Which health tech sub-sector is growing fastest?
AI and data analytics in healthcare has attracted the most investment and the highest concentration of top-performing companies in recent rankings, as reported by TechCrunch. Telehealth and mental health tech also continue to grow, though at a pace that has moderated from the 2020–2021 peak.
